Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

By LabMedica International staff writers
Posted on 02 Oct 2023

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. More...

T-Cells, a special kind of white blood cell, are crucial for directing these immune reactions. These cells have specialized structures called T-Cell receptors that enable them to spot and bind to antigens on infected or abnormal cells. Evaluating T-Cells could offer a more precise understanding of immunity because the immune response from T-Cells generally endures longer than that from antibodies. Now, a new test intended to detect the body’s adaptive immune response to viruses can help respond to future viral threats.

Virax Biolabs (London, UK) is developing the ViraxImmune test, which is designed to measure T-Cell activation when a blood sample encounters a set of proteins simulating viral exposure in the body. Unlike antibodies, T-Cells serve as coordinators of the immune system's fight against viral invasion. Detecting these cells could provide insights into natural resistance against diseases for those who haven't been infected and could also help gauge the level of long-term immunity that someone has after recovering from a viral infection. The ViraxImmune test aims to identify T-Cells that remain in the body long after the initial immune response from antibodies, due to vaccination or infection, has faded. This is expected to offer a more accurate view of long-term immunity compared to just measuring antibody levels.

The ViraxImmune test has additional capabilities. It can identify if someone had been previously exposed to a virus even when initial antibody responses have faded or vanished. It's also possible that someone could have some level of immunity to a virus without ever having been exposed to it. For healthcare providers, the test serves as a sophisticated diagnostic tool that can detect early immune responses, sometimes even before antibodies have a chance to develop. This can enable healthcare providers to make decisions that are tailored to each patient's specific immune characteristics. For individuals being tested, this opens up the possibility of earlier interventions, more closely monitored conditions, and treatment plans that are customized to their needs. The test is structured to fit smoothly into current healthcare workflows, delivering timely and accurate results.

Related Links:
Virax Biolabs 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.